Archives
Gemcitabine HCl: Reliable Cytotoxicity Workflows
2026-08-22
This scenario-based guide shows how Gemcitabine HCl, SKU A1402, can support better-planned cytotoxicity, DNA replication inhibition, and pancreatic cancer studies. It connects concentration selection, solution handling, data interpretation, and MRI-guided in vivo validation without treating one assay endpoint as a substitute for another.
Q-VD(OMe)-OPh in Apoptosis Research
2026-08-22
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for testing caspase dependence in apoptosis assays. The compound, also called quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone, combines recombinant-caspase potency with practical solvent and storage guidance.
CHI3L1-IN-5: From Target to Astrocyte Rescue
2026-08-21
CHI3L1-IN-5 (Compound Z17) is a selective CHI3L1 inhibitor that links NF-κB suppression with restoration of astrocyte amyloid clearance. This article explains the mechanistic evidence, assay logic, translational value, and practical limitations behind its use in Alzheimer’s disease research.
Cefepime in CNS Infection and Resistance Models
2026-08-20
Cefepime (BMY-28142) offers a useful bridge between blood-brain barrier-aware infection models and contemporary resistance research. This article outlines how translational teams can use the compound to connect exposure, bacterial killing, neurotoxicity risk, and carbapenemase-mediated transmission dynamics.
Sodium Picosulfate and the Gut–Liver–Brain Axis
2026-08-20
Sodium Picosulfate is best understood not only as a bowel-output reagent, but also as a controllable perturbation of intestinal water and electrolyte handling. This thought-leadership article connects its established constipation-research utility with gut–liver–brain studies, using the 2025 [18F]PBR146 neuroinflammation work as a framework while clearly separating evidence from hypothesis.
Anagliptin (SK-0403): DPP-4 and Vascular Research
2026-08-19
Anagliptin (SK-0403) is a potent, selective, orally active DPP-4 inhibitor reported to have an IC50 of 3.8 nM in the supplier assay. Rabbit-aorta experiments further associate its vasorelaxation with Kv channel activity and SERCA pump function, while separating those findings from clinical efficacy.
EPZ5676: Practical DOT1L Inhibitor Workflows
2026-08-19
EPZ5676 combines subnanomolar DOT1L potency with strong methyltransferase selectivity, making it a practical tool for linking H3K79 methylation inhibition to MLL-rearranged leukemia phenotypes. This guide covers formulation, biochemical and cellular workflows, orthogonal validation, and troubleshooting for reproducible results.
Gamithromycin PK/PD Cutoffs in Piglet H. parasuis
2026-08-18
Zhou et al. integrated susceptibility surveillance, serum pharmacodynamics, piglet pharmacokinetics, and population dose modeling to define epidemiological and PK/PD cutoffs for gamithromycin against Haemophilus parasuis. The study links an AUC24h/MIC exposure index to bacteriological outcomes and shows that a modest adjustment above the marketed dose could improve target attainment.
HSP90 Regulation of RNA Foci in DM1
2026-08-18
A microscopy-based small-molecule screen identified HSP90 as a differentiation-dependent regulator of DMPK mRNA and toxic CUG-repeat RNA foci in myotonic dystrophy type 1 cells. Genetic validation and pathway analysis connected HSP90 activity to p-STAT3 in undifferentiated myoblasts, while differentiated cells showed an opposite, p-STAT3-independent response.
Trelagliptin Succinate: From Glycemia to Translation
2026-08-17
Trelagliptin succinate, also known as SYR-472 succinate, offers translational researchers a framework for linking selective DPP-4 enzyme inhibition with incretin biology, adipocyte insulin signaling, and practical diabetes mellitus research workflows.
Ratiometric Imaging of Amyloid-β Fibrils
2026-08-17
The reference study introduces dual-emissive tris-heteroleptic ruthenium complexes for ratiometric detection and confocal imaging of Aβ fibrils. By combining an aggregation-responsive phosphorescence signal with a comparatively stable fluorescence reference, the approach improves interpretability while revealing different responses to Aβ40 and Aβ42 assemblies.
Anagliptin Vasorelaxation via Kv Channels and SERCA
2026-08-16
A 2025 Acta Diabetologica study shows that Anagliptin produces dose-dependent relaxation in phenylephrine-contracted rabbit aortic rings. Pharmacological experiments implicate voltage-dependent K+ channels and the SERCA pump, while excluding several other K+ channel classes, cyclic-nucleotide pathways, and the endothelium as necessary mediators.
Annexin V-FITC/7-AAD Apoptosis Kit: Mechanistic Readout
2026-08-15
The Annexin V-FITC/7-AAD Apoptosis Kit converts membrane changes into a resolved map of viable, early apoptotic, late apoptotic, and necrotic cells. This article shows how to interpret that map alongside the Src/JNK and mitochondrial apoptosis findings reported for Corynoline-treated osteosarcoma cells.
Aprotinin: Protease Control Meets RBC Mechanics
2026-08-14
Aprotinin and bovine pancreatic trypsin inhibitor research can benefit from pairing protease control with red blood cell membrane biophysics. This article translates membrane-bending findings into practical assay-design decisions for fibrinolysis inhibition, inflammation studies, and cardiovascular surgery blood management research.
Anagliptin Vasorelaxation: Kv Channels and SERCA
2026-08-14
A 2025 Acta Diabetologica study identifies a previously undercharacterized vascular action of anagliptin in rabbit aortic rings, linking relaxation to voltage-dependent potassium channels and the SERCA pump. The findings provide a focused framework for vasorelaxant mechanism research while indicating that the response is independent of the endothelium and classical cyclic-nucleotide pathways.
610 records 11/41 page Previous Next First page 上5页 1112131415 下5页 Last page